围绝经期激素避孕药使用的系统综述
9篇评估症状缓解的研究中6篇显示激素避孕优于不治疗;7篇评估长期结局的研究中6篇显示激素避孕有显著改善。基于有限数据,左炔诺孕酮宫内节育器联合补充低剂量绝经雌激素对症状和长期结局有积极结果。
要点
- 激素避孕可改善围绝经期症状管理,但需排除禁忌证。
- 左炔诺孕酮宫内节育器联合低剂量雌激素可能对症状和长期结局有益。
- 选择避孕方法需考虑患者风险因素、症状特征、长期风险获益和偏好。
核心结论
- 激素避孕在无禁忌证的围绝经期女性中可改善症状管理和长期结局。
- 基于有限数据且缺乏对照研究,左炔诺孕酮宫内节育器联合补充低剂量绝经雌激素对 disruptive 围绝经期症状管理和长期结局有积极结果。
主要发现
- 9篇文章评估症状缓解,其中6篇报告激素避孕相比不治疗有统计学显著改善。
- 7项研究评估长期结局(包括骨丢失和代谢参数),其中6项显示激素避孕有统计学显著改善。
临床怎么用
- 临床医生和药师为围绝经期女性选择避孕方法时,需处理患者特定风险因素、症状特征、长期风险获益和患者偏好。
- 对于无禁忌证的围绝经期女性,可考虑使用激素避孕以改善症状管理和长期结局。
局限性
- 数据有限且缺乏比较性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hormonal contraceptives have been used in perimenopausal women to manage a variety of symptoms and prevent unintended pregnancy. However, it is unclear what contraceptive regimen is best for these women. To evaluate hormonal contraceptive methods in women experiencing perimenopause using two prespecified outcomes: perimenopausal symptom management and long-term effects. A literature search of PubMed and EMBASE databases was performed (January 1990 to October 2021) using search terms "perimenopause" and "contraception." Relevant full-text articles in English were included. Fifteen clinical articles were reviewed: Fourteen were internationally based, and one study was conducted in the United States. Nine articles evaluated symptom resolution, and six of these nine reported statistically significant changes in favor of treating perimenopausal women with hormonal contraceptives compared with no treatment. Seven studies evaluated long-term outcomes including bone loss and metabolic parameters, and six of these seven showed statistically significant improvements with hormonal contraceptives. Based on limited data and a lack of comparative studies, the use of a levonorgestrel intrauterine device with supplemental low-dose menopausal estrogen has positive results for the management of disruptive perimenopausal symptoms and long-term outcomes. Hormonal contraception in perimenopausal women improves symptom management and long-term outcomes if patients do not have contraindications. When selecting a contraceptive for women in perimenopause, clinicians and pharmacists need to address specific patient risk factors, symptom profiles, long-term risks and benefits, and patient preferences.
引用
- Guerin J, Engelmann A, Mattamana M, et al. Use of hormonal contraceptives in perimenopause: A systematic review. Pharmacotherapy. 2022. PMID: 34967466. doi:10.1002/phar.2657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。